Vaccine Marketing - Innovation and Marketing in the Pharmaceutical Industry - page 412

Kennedy A, Stokley S, Curtis CR, Gust D (2012) Limited awareness of vaccines recommended for
adolescents and other results from two national consumer health surveys in the United States.
J Adolesc Health 50(2):198-200
KFF (2011) Fact sheet. The HPV vaccine: access and use in the U.S. http://kaiserfamilyfounda-
tion.fi les.wordpress.com/2013/01/7602-03.pdf . Accessed 4 July 2013
Kharbanda EO, Stockwell MS, James C, Natarajan K, Rickert VI (2010) Changes in tdap and
MCV4 vaccine coverage following enactment of a statewide requirement of tdap vaccination
for entry into sixth grade. Am J Public Health 100(9):1635-1640
Koehler JJ, Gershoff AD (2003) Betrayal aversion: when agents of protection become agents of
harm. Organ Behav Hum Decis Process 90(2):244
Kremer M (2001a) Creating markets for new vaccines: part I: rationale. In: Stern S (ed) Innovation
policy and the economy, vol 1. MIT for the National Bureau of Economic Research, London,
pp 35-72
Kremer M (2001b) Creating markets for new vaccines: part II: design issues. In: Stern S (ed)
Innovation policy and the economy, vol 1. MIT for the National Bureau of Economic Research,
London, pp 73-118
Kresse H, Shah M (2010) Strategic trends in the vaccine market. Nat Rev Drug Discov
9:913-914
Kyle MK, Ridley DB (2007) Would greater transparency and uniformity of health care prices
benefi t poor patients? Health Aff 26(5):1384-1391
Lantos JD, Jackson MA, Opel DJ, Marcuse EK, Myers AL, Connelly BL (2010) Controversies in
vaccine mandates. Curr Probl Pediatr Adolesc Health Care 40(3):38-58
Larson HJ, Cooper LZ, Eskola J, Katz SL, Ratzan S (2011) Addressing the vaccine confi dence
gap. Lancet 378(9790):526-535
Laurent-Ledru V, Thomson A, Monsonego J (2011) Civil society: a critical new advocate for vac-
cination in Europe. Vaccine 29(4):624-628
Leask J, Chapman S, Cooper Robbins SC (2010) “All manner of ills”: the features of serious dis-
eases attributed to vaccination. Vaccine 28(17):3066-3070
Lefevere E, Hens N, De Smet F, Van Damme P (2011) Dynamics of HPV vaccination initiation in
Flanders (Belgium) 2007-2009: a cox regression model. BMC Public Health 11(1):470
Levine OS, Bloom DE, Cherian T, de Quadros C, Sow S, Wecker J et al (2011) The future of
immunisation policy, implementation, and fi nancing. Lancet 378(9789):439-448
Lichtenberg FR (2011) Pharmaceutical companies' variation of drug prices within and among
countries can improve long-term social well-being. Health Aff 30(8):1539-1544
Lieu TA, McGuire TG, Hinman AR (2005) Overcoming economic barriers to the optimal use of
vaccines. Health Aff 24(3):666-679
Light DW, Andrus JK, Warburton RN (2009) Estimated research and development costs of rotavirus
vaccines. Vaccine 27(47):6627-6633
Lindley MC, Shen AK, Orenstein WA, Rodewald LE, Birkhead GS (2009) Financing the delivery
of vaccines to children and adolescents: challenges to the current system. Pediatrics 124(Suppl
5):S548-S557
Lydon P, Beyai PL, Chaudhri I, Cakmak N, Satoulou A, Dumolard L (2008) Government fi nancing
for health and specifi c national budget lines: the case of vaccines and immunization. Vaccine
26(51):6727-6734
MacDonald NE, Smith J, Appleton M (2012) Risk perception, risk management and safety assess-
ment: what can governments do to increase public confi dence in their vaccine system? Biologicals
40(5):384-388
Maltezou HC, Dedoukou X, Patrinos S, Maragos A, Poufta S, Gargalianos P et al (2010)
Determinants of intention to get vaccinated against novel (pandemic) infl uenza A H1N1 among
health-care workers in a nationwide survey. J Infect 61(3):252-258
Marquez-Calderon S, Lopez-Valcarcel BG, Segura A (2009) Medical societies' recommendations
for immunization with human papillomavirus vaccine and disclosure of confl icts of interests.
Prev Med 48(5):449-453